Xencor (XNCR) Shares Up 7.6%
Xencor Inc (NASDAQ:XNCR) shot up 7.6% on Friday . The company traded as high as $30.09 and last traded at $29.98. 681,554 shares changed hands during mid-day trading, an increase of 208% from the average session volume of 221,113 shares. The stock had previously closed at $27.85.
A number of brokerages have weighed in on XNCR. Cantor Fitzgerald reissued an “overweight” rating on shares of Xencor in a report on Friday, November 23rd. BidaskClub raised shares of Xencor from a “hold” rating to a “buy” rating in a report on Tuesday, January 1st. Nomura downgraded shares of Xencor from a “neutral” rating to a “reduce” rating and cut their price target for the company from $28.00 to $21.00 in a report on Friday, February 22nd. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Thursday, December 20th. Finally, Raymond James began coverage on shares of Xencor in a report on Thursday. They issued an “outperform” rating and a $40.00 price target for the company. Two investment analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. Xencor has an average rating of “Buy” and an average target price of $41.78.
The firm has a market capitalization of $1.57 billion, a PE ratio of -22.89 and a beta of 1.40.
COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Shares Up 7.6%” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/xencor-xncr-shares-up-7-6/2897239.html.
About Xencor (NASDAQ:XNCR)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: Is the QQQ ETF safe?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.